RNA Interference for the Treatment of Papillomavirus Disease
Richa Singhania 1, §, Norliana Khairuddin 2, §, Daniel Clarke 3, §, Nigel AJ McMillan*, 3
Identifiers and Pagination:Year: 2012
Issue: Suppl 2
First Page: 204
Last Page: 215
Publisher Id: TOVJ-6-204
Article History:Received Date: 1/5/2012
Revision Received Date: 10/8/2012
Acceptance Date: 15/8/2012
Electronic publication date: 28/12/2012
Collection year: 2012
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http: //creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Human Papillomavirus (HPV)-induced diseases are a significant burden on our healthcare system and current therapies are not curative. Vaccination provides significant prophylactic protection but effective therapeutic treatments will still be required. RNA interference (RNAi) has great promise in providing highly specific therapies for all HPV diseases yet this promise has not been realised. Here we review the research into RNAi therapy for HPV in vitro and in vivo and examine the various targets and outcomes. We discuss the idea of using RNAi with current treatments and address delivery of RNAi, the major issue holding back clinical adoption. Finally, we present our view of a potential path to the clinic.